Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SAR leading to new topoisomerase I inhibitor presented by Banyu

Dec. 29, 1997

Peptidomimetic protein farnesyltransferase inhibitors in development at Merck

Dec. 24, 1997

ICI-182780 associated with longer remission duration than megestrol in resistant breast cancer

Dec. 22, 1997

Peptidomimetic inhibitors of protein farnesyltransferase from Merck & Co.

Dec. 22, 1997

Squalamine enters phase I for the treatment of cancer

Dec. 22, 1997

FDA Advisory Committee does not recommend approval for DepoCyt

Dec. 19, 1997

Farnesyltransferase inhibitors lacking a thiol moiety from Merck & Co.

Dec. 19, 1997

More on protein farnesyltransferase inhibitors from Merck & Co.

Dec. 18, 1997

Chemoprotective properties of lisofylline reported

Dec. 18, 1997

Indomethacin: antitumor activity and effects on telomerase

Dec. 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...